Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 4,247 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Rilvegostomig, Volrustomig, Sabestomig, AZD9592, Pembrolizumab, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab; Biological · Combination Product
Lead sponsor: Presage Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 7
States / cities: Sacramento, California • The Bronx, New York • Chapel Hill, North Carolina + 3 more

Conditions: Muscle Soreness
Interventions: Diclofenac sodium gel 1%, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Pasadena, California

Conditions: COVID-19
Interventions: Niclosamide, Placebo, Telehealth monitoring; Drug · Other
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Systemic Sclerosis
Interventions: RO7303509, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Palo Alto, California • New York, New York • Dallas, Texas

Conditions: Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
Interventions: Metyrapone 250 mg Oral Tablets, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Idiopathic Pulmonary Fibrosis, Hypoxemia
Interventions: GBT440, Placebo; Drug
Lead sponsor: Global Blood Therapeutics; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 12
States / cities: Birmingham, Alabama • San Francisco, California • Denver, Colorado + 9 more

Conditions: Dry Eye Syndrome
Interventions: TOP1630 0.1% Ophthalmic Solution TID OU, Placebo to TOP1630 0.1% Ophthalmic Solution TID OU; Drug
Lead sponsor: Topivert Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 4
States / cities: Lewiston, Maine • Andover, Massachusetts • Raynham, Massachusetts + 1 more

Conditions: Friedreich Ataxia
Interventions: TAK-831, TAK-831 Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • Gainesville, Florida • Tampa, Florida + 3 more

Conditions: Atrial Fibrillation, Heart Failure
Interventions: FDA approved rate and rhythm control drugs, AV Node ablation and device implant; Drug · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 65 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 5
States / cities: Scottsdale, Arizona • Evansville, Indiana • Rochester, Minnesota + 2 more

Conditions: HIV Infections
Interventions: Tenofovir disoproxil fumarate; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 58
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 38 more

Conditions: Bilateral Ovarian Disease
Interventions: Anti adhesion agent; Biological
Lead sponsor: OMRIX Biopharmaceuticals; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Damage Muscle, Body Weight Changes, Performance Enhancing Product Use
Interventions: Pre-workout plus and Protein recovery plus, Placebo, 6-week resistance training program; Dietary Supplement · Other
Lead sponsor: Pharmanex; Industry
Eligibility: 25 Years to 50 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: C-Section, Pain Management
Interventions: Exparel + Bupivacaine, Bupivacaine; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 186 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 12
States / cities: Loma Linda, California • Stanford, California • Boston, Massachusetts + 7 more

Conditions: Infection
Interventions: Cefazolin 2g for Injection USP and Dextrose Injection USP, Cefazolin 1.5g; Drug
Lead sponsor: B. Braun Medical Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Interventions: Satralizumab, Placebo, Baseline Treatment; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years to 74 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Plaque Psoriasis, Psoriasis, Skin Diseases
Interventions: JTE-451 Tablets, Placebo Tablets; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Santa Monica, California • Temecula, California • Indianapolis, Indiana + 3 more

Conditions: Depression, End Stage Renal Disease
Interventions: Engagement Interview, Cognitive Behavioral Therapy, Antidepressant Drug Therapy; Behavioral · Drug
Lead sponsor: University of Washington; Other
Eligibility: 21 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Albuquerque, New Mexico • Dallas, Texas • Seattle, Washington

Conditions: Snakebite, Envenoming, Snake
Interventions: Varespladib intravenous form, varespladib-methyl- oral form, Placebo intravenous form, Placebo - oral form; Drug
Lead sponsor: Ophirex, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Phoenix, Arizona • Tucson, Arizona • Palm Springs, California + 7 more

Conditions: Cystic Fibrosis
Interventions: LAU-7b, Placebo oral capsule; Drug
Lead sponsor: Laurent Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 27
States / cities: Long Beach, California • Los Angeles, California • Sacramento, California + 24 more

Conditions: Clostridium Difficile Infection
Interventions: SER-262, Placebo; Drug
Lead sponsor: Seres Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 22
States / cities: Athens, Alabama • Fountain Valley, California • La Mesa, California + 19 more

Conditions: Nonalcoholic Fatty Liver Disease
Interventions: BMS-963272, Placebo matching BMS-963272; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 19
States / cities: Cullman, Alabama • Chandler, Arizona • Tucson, Arizona + 14 more

Conditions: Gastro-enteropancreatic Neuroendocrine Tumor
Interventions: Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution, High dose 60 mg octreotide long-acting repeatable; Drug
Lead sponsor: Advanced Accelerator Applications; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 6
States / cities: New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more

Conditions: Substance Abuse
Interventions: Strengthening Families Program Online eLearning Game, SFP Home-use DVD, Wait-Listed Control; Behavioral
Lead sponsor: Strengthening Families Program LLC; Industry
Eligibility: 11 Years and older
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Cholesterol, Hyperlipidemia, Hypercholesteremia
Interventions: Ad-Chol-Pre, Half-dose Ad-Chol-Pre, Defatted egg yolk without the active ingredient of the other two interventions; Dietary Supplement · Other
Lead sponsor: Integrative Health Technologies, Inc.; Network
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness

Niclosamide for Mild to Moderate COVID-19

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis

Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS

Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF

Study of TOP1630 for Dry Eye Syndrome

Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia

AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study

Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected Patients

Pilot Study Evaluating the Safety and Potential Trends in Efficacy of Adhexil

Chronic Study on Body Composition, Training, Performance, and Recovery

Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the TAP vs. Bupivacaine Alone in Subjects Undergoing Elective C-Sections

Pharmacokinetics and Safety of Cefazolin 2g in DUPLEX

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis

A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}

Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)

Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults

SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

Strengthening Families Program Online

Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health